Stock comparison
Haemonetics
MiMedx Group
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
MDXG
MiMedx Group
Market cap
$539.18M
Sector
Healthcare
Overall winner
Haemonetics HAE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | MDXG | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 57C | HAE |
| Benjamin Graham | 85A | 50D | HAE |
| Philip Fisher | 60C | 54C | HAE |
| Peter Lynch | 54C | 48D | HAE |
| Joel Greenblatt | 31F | 22F | HAE |
| Charlie Munger | 54D | 44D | HAE |
| Terry Smith | 55D | 51D | HAE |
Side-by-side metrics
| Metric | HAE | MDXG |
|---|---|---|
| Market cap | $2.98B | $539.18M |
| P/E (TTM) | 24.8x | 17.6x |
| EV/EBIT | 14.1x | 6.0x |
| ROIC (TTM) | 8.37% | 10.81% |
| Gross margin | 55.74% | 81.04% |
| Net margin | 7.29% | 7.88% |
| Revenue CAGR 5y | 7.65% | 14.68% |
| EPS CAGR 5y | 24.62% | - |
| Debt / Equity | 1.5x | 0.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- Market cap$2.98Bvs $539.18M+82%
MDXG leads on
- Debt / Equity0.0xvs 1.5x+100%
- EV/EBIT6.0xvs 14.1x+57%
- Revenue CAGR 5y14.68%vs 7.65%+48%
- Gross margin81.04%vs 55.74%+31%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.